



# Macroplastique®

TREATMENT OF FEMALE  
URINARY STRESS INCONTINENCE



*Innovation for Health*

# PREDICTABLE PRODUCT. PROVEN PERFORMANCE.

The use of Macroplastique in the treatment of stress urinary incontinence (SUI) is a simple procedure that avoids the degree of complications and the post-procedure convalescence associated with alternative treatments. In correctly diagnosed and selected patients, this procedure provides a simple outpatient day case solution in both primary and secondary indications.

## MACROPLASTIQUE® URETHRAL BULKING AGENT TREATMENT OF FEMALE SUI

### SUPERIOR PERFORMANCE AT 1 YEAR<sup>1</sup>

In a randomised, controlled multi-centre trial (RCT), the Macroplastique group (n=122) outperformed the collagen control group (n=125)

- 80% of patients were dry or markedly improved based on physician evaluation
- 62% of patients improved by at least 1 Stamey Grade; statistically superior results compared to 48% of collagen group ( $p < 0.05$ )

### IMPROVED OUTCOMES AT 2 YEARS<sup>2</sup>

In the RCT, Macroplastique patients followed to 2 years (n= 84) maintained excellent outcomes

- 75% of patients had an improvement of at least 1 Stamey Grade


### SUSTAINED RESULTS AT 5 YEARS<sup>3</sup>

- 83.3% success for Type I
- 80% success for Type III

1. Ghoniem, G., Corcos, J., Comiter, C., Bernhard, P., Westney, O.L. & Herschorn, S. (2009). Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: Results of a multicenter, randomized, controlled, single-blind study. *JUrol*, 181, 204-210.
2. Uroplasty, Inc. (2006). Macroplastique Premarket Approval Study.
3. Zafirakis, H.G., Nathan, S., & Shah, J. (2002). Long-term efficacy of submucosal urethral injection for genuine stress incontinence in women. AUA abstract, Florida, USA.
4. Ghoniem, G., Bernhard, P., Corcos, J., Comiter, C., Tomera, K., Westney, O., et al. (2005). Multicenter randomized controlled trial to evaluate Macroplastique urethral bulking agent for the treatment of female stress urinary incontinence. *Int Urogynec J*, 16 (Suppl 2), S129-S130.
5. Chapple, C., Brubaker, L., Haab, F., Van Kerrebroeck, P., & Robinson, D. (2007). Patient-perceived outcomes in the treatment of stress urinary incontinence: Focus on urethral injection therapy. *Int Urogynecol J Pelvic Floor Dysfunct*, 18(2), 199-205.

For complete instructions for use, storage, warnings, indications, contraindications, precautions, adverse reactions and disclaimer of warranties, please refer to the insert accompanying each Macroplastique. Models are for illustrative purpose only. Macroplastique is a registered trademark. Macroplastique is manufactured by Uroplasty LLC. ©2018 LABORIE. All rights reserved.

CLINICAL IMPROVEMENT  
Physician and Patient Assessment<sup>5</sup>



*"Urethral injection therapy has been shown to provide statistically significant and clinically meaningful improvements in QoL. Indeed, the QoL improvement is similar to that with surgery."<sup>5</sup>*

*"Macroplastique has been shown to be a safe and effective treatment for female stress urinary incontinence, with sustained results through two years."<sup>4</sup>*



EUROPE/INTERNATIONAL:  
Tel.: +31 53 4803700  
Email: info@laborie.com

HEADQUARTERS:  
Tel.: +1 905 612 1170  
Email: marketing@laborie.com



www.laborie.com